Prolonged interleukin-6 administration enhances glucose tolerance and increases skeletal muscle PPARα and UCP2 expression in rats
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Chronic elevations in interleukin (IL)-6 have been associated with insulin resistance, but acute IL-6 administration can enhance insulin sensitivity. Our aim was to exogenously administer IL-6 to rats to elicit either chronic or repeated acute elevations in systemic IL-6. We hypothesized that a continuous elevation of IL-6 would inhibit glucose tolerance and insulin sensitivity while acute intermittent elevations would improve it. Male Wistar rats were treated for 14d with recombinant human IL-6 (2.4 μg/day) or saline administered either by miniosmotic pump (continuous IL-6) or via twice-daily injection (intermittent IL-6). Glucose and insulin tolerance tests were performed following 14-d treatment and 24 h later rats were administered a bolus of insulin (150 mU/g) or saline intraperitoneally. Approximately, 10 min after insulin injection soleus, gastrocnemius and liver were excised and rapidly frozen in liquid nitrogen for subsequent metabolic measures. Irrespective of the mode of delivery, IL-6 treatment increased basal insulin sensitivity, as measured by the homeostatic model assessment of insulin resistance, and enhanced glucose clearance during an i.p. glucose tolerance test. IL-6 increased circulating fatty acids, but did not increase triglyceride accumulation in either skeletal muscle or liver, while it increased the protein expression of both PPARα and UCP2 in skeletal muscle, suggesting that IL-6 can enhance fat oxidation via mitochondrial uncoupling. These data demonstrate that, irrespective of the mode of delivery, IL-6 administration over 2 weeks enhances glucose tolerance. Our results do not support the notion that prolonged chronically elevated IL-6 impairs insulin action in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB
Cai, D., Yuan, M., Frantz, D. F., Melendez, P. A., Hansen, L., Lee, J., & Shoelson, S. E. (2005) · Nature Medicine · doi:10.1038/nm1166 · Cited by 2,245 · cited 1×
“…et al. 2003),while treatingmice DOI: 10.1677/JOE-08-0113 Britain Online version via http://www.endocrinology-journals.org that harbour genetic mutations resulting in hepatic insulin resistance, with IL-6 neutralizing antibodies improves such a phenotype (Cai et al. 2005, Klover et al. 2005).”
BackgroundInfluentialInterleukin-6-deficient mice develop mature-onset obesity
Wallenius, V., Wallenius, K., Ahrén, B., Rudling, M., Carlsten, H., Dickson, S. L., Ohlsson, C., & Jansson, J.-O. (2002) · Nature Medicine · doi:10.1038/nm0102-75 · Cited by 1,213 · cited 2×
“…Carey et al. 2006, Glund et al. 2007) and fat oxidation (Bruce &Dyck 2004, Petersen et al. 2005, Al-Khalili et al. 2006), principally via the activation of AMP-activated protein kinase (AMPK) (Carey et al. 2006), while IL-6 knockout mice become obese and glucose intolerant (Wallenius et al. 2002).”
BackgroundCarey, A. L., Steinberg, G. R., Macaulay, S. L., Thomas, W. G., Holmes, A. G., Ramm, G., Prelovsek, O., Hohnen-Behrens, C., Watt, M. J., James, D. E., et al. (2006) · Diabetes · doi:10.2337/db05-1404 · Cited by 898 · cited 12×
“…sawnodifferenceswhen comparing the three groups for the phosphorylation of STAT3 (Tyr705) in skeletal muscle and we have previously shown a relationship between STAT3 phosphorylation and AMPK activation when treating animals with gp130 receptor cytokines (Carey et al. 2006, Watt et al. 2006a).”
BackgroundMethodInfluentialSelf-citationInterleukin-6 stimulates lipolysis and fat oxidation in humans
van Hall, G., Steensberg, A., Sacchetti, M., Fischer, C., Keller, C., Schjerling, P., Hiscock, N., Møller, K., Saltin, B., Febbraio, M. A., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021687 · Cited by 767 · cited 1×
“These data are consistent with previous reports that IL-6 increases lipolysis and lipid oxidation in vitro, in vivo and in skeletal muscle ex vivo (van Hall et al. 2003, Bruce & Dyck 2004, Petersen et al. 2005).”
ResultSelf-citationUeki, K., Kondo, T., & Kahn, C. R. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.12.5434-5446.2004 · Cited by 686 · cited 3×
“…IL-6 results in elevated expression of suppressor of cytokine signalling-3 (SOCS3) (Klover et al. 2003), which is generally thought to induce insulin resistance (Ueki et al. 2004), while acute doses of IL-6 may not result in a sustained increase in SOCS3 necessary to disrupt insulin signalling.”
BackgroundSenn, J. J., Klover, P. J., Nowak, I. A., Zimmers, T. A., Koniaris, L. G., Furlanetto, R. W., & Mooney, R. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210689200 · Cited by 620 · cited 2×
“2006), without altering insulin sensitivity, others have shown that the IL-6 mediated insulin resistance in hepatocytes was associated with increased SOCS3 expression (Senn et al. 2003).”
BackgroundChronic Exposure to Interleukin-6 Causes Hepatic Insulin Resistance in Mice
Klover, P. J., Zimmers, T. A., Koniaris, L. G., & Mooney, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.11.2784 · Cited by 488 · cited 11×
“2005) which has been linked to elevated liver SOCS3 expression (Klover et al. 2003).”
BackgroundMethodResultInfluentialBruce, C. R., Carey, A. L., Hawley, J. A., & Febbraio, M. A. (2003) · Diabetes · doi:10.2337/diabetes.52.9.2338 · Cited by 318
Self-citationPetersen, E. W., Carey, A. L., Sacchetti, M., Steinberg, G. R., Macaulay, S. L., Febbraio, M. A., & Pedersen, B. K. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00257.2004 · Cited by 311
Self-citationAMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise.
Kelly, M., Keller, C., Avilucea, P. R., Keller, P., Luo, Z., Xiang, X., Giralt, M., Hidalgo, J., Saha, A. K., Pedersen, B. K., et al. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.05.188 · Cited by 289
Cited by
Regulation of metabolism by the innate immune system
Lackey, D. E., & Olefsky, J. M. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.189 · Cited by 667
González, F. (2012) · Steroids · doi:10.1016/j.steroids.2011.12.003 · Cited by 515
Insulin Resistance, Obesity and Lipotoxicity
Yazıcı, D., & Sezer, H. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-48382-5_12 · Cited by 499
Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance
Matthews, V. B., Allen, T. L., Risis, S., Chan, M. H. S., Henstridge, D. C., Watson, N., Zaffino, L. A., Babb, J. R., Boon, J., Meikle, P. J., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1865-y · Cited by 334
Awazawa, M., Ueki, K., Inabe, K., Yamauchi, T., Kubota, N., Kaneko, K., Kobayashi, M., Iwane, A., Sasako, T., Okazaki, Y., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.02.010 · Cited by 277
“There is also still much debate as to whether chronically elevated IL-6 levels could actually contribute to systemic insulin resistance in obesity (Holmes et al., 2008; Torisu et al., 2007); this concept awaits future research.”
Metadata
- Authors
- Holmes, A. G., Mesa, J. L., Neill, B. A., Chung, J., Carey, A. L., Steinberg, G. R., Kemp, B. E., Southgate, R. J., Lancaster, G. I., Bruce, C. R., Watt, M. J., & Febbraio, M. A.
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 2008-06-03
- Volume
- 198
- Issue
- 2
- Pages
- 367-374
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W2107010539
- Cited by
- 70
- References
- 14
- FWCI
- 3.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prolonged interleukin-6 administration enhances glucose tolerance and increases skeletal muscle PPARα and UCP2 expression in rats. https://app.cochat.ai/papers/10.1677/joe-08-0113
- The paper
- Holmes, A. G., Mesa, J. L., Neill, B. A., Chung, J., Carey, A. L., Steinberg, G. R., Kemp, B. E., Southgate, R. J., Lancaster, G. I., Bruce, C. R., Watt, M. J., & Febbraio, M. A. (2008). Prolonged interleukin-6 administration enhances glucose tolerance and increases skeletal muscle PPARα and UCP2 expression in rats. Journal of Endocrinology. https://doi.org/10.1677/joe-08-0113
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.